Björn von Siemens
Managing Director
Company profile
Company profile
Surgical.ai is a surgical technology investment and innovation accelerator focused on transforming the future of surgery through artificial intelligence. The company invests in and guides the most innovative companies developing surgical technologies, with a particular focus on the most complex, critical, and costly spaces in modern medicine. Their vision is to create a world where healing is a reliable expectation rather than a hope, making surgery as safe and successful as flying. By weaving artificial intelligence throughout existing surgical infrastructure, Surgical.ai aims to reduce costs while ushering in an entirely new level of human healthcare. The company believes in a future where insurance is functional and doctors can focus on practicing medicine rather than processing paperwork. Based in Berlin, Germany, Surgical.ai operates as an investment holding company that accelerates progress in surgical innovation through strategic investments and guidance of portfolio companies developing next-generation surgical technologies.
Company description Surgical.ai official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
No clinical focus areas are currently listed.
Deployment information is currently being developed.
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
NPJ digital medicine · Aug 10, 2026
Photoacoustic device fingerprints induce bias in deep learning models.Scientific reports · Jun 13, 2026
Online patient education resources in bariatric surgery: a systematic evaluation of quality, readability, transparency, and representation.Surgical endoscopy · Jun 1, 2026
Erratum: Learning to simulate realistic human diffuse reflectance spectra (Erratum).Journal of biomedical optics · Mar 1, 2026
Reporting checklist for foundation and large language models in medical research (REFINE): an international consensus guideline.Diagnostic and interventional radiology (Ankara, Turkey) · Feb 26, 2026
Learning to simulate realistic human diffuse reflectance spectra.Journal of biomedical optics · Feb 1, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Reducing cost through AI integration in surgical infrastructure
Vision to make surgery as safe and successful as flying
05 · Leadership
Leadership profiles and professional links from the current Company record.
Björn von Siemens
Managing Director
Dennis Kogan
Managing Director
06 · Company updates
Recent articles published on Surgical.ai's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies developing surgical technologies enhanced by AI, including robotic surgical systems, AI-powered surgical assistance and navigation tools, autonomous surgical robotics, and surgical data and analytics platforms. Covers both the performance of surgery and the analysis of surgical outcomes and OR efficiency.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.